Neuroendocrine and Aggressive-Variant Prostate Cancer
In prostate cancer, neuroendocrine (NE) differentiation may rarely present de novo or more frequently arises following hormonal therapy in patients with castration-resistant prostate cancer (CRPC). Its distinct phenotype is characterized by an aggressive clinical course, lack of responsiveness to ho...
Main Authors: | Nicholas Spetsieris, Myrto Boukovala, Georgios Patsakis, Ioannis Alafis, Eleni Efstathiou |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/12/3792 |
Similar Items
-
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer
by: Rodolfo Montironi, et al.
Published: (2020-04-01) -
Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment
by: Tomoyuki Makino, et al.
Published: (2021-04-01) -
Development and prevalence of castration-resistant prostate cancer subtypes
by: Jordan E. Vellky, et al.
Published: (2020-11-01) -
Mixed adenocarcinoma and neuroendocrine prostate cancer: a case report
by: Rittu Hingorani, et al.
Published: (2014-11-01) -
Long non-coding RNAs in castration-resistant and neuroendocrine prostate cancer: Potential role and therapeutic impact
by: Kumari S. Prajapati, et al.
Published: (2020-12-01)